On Friday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened lower -7.14% from the last session, before settling in for the closing price of $9.52. Price fluctuations for ZNTL have ranged from $9.47 to $30.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. Company’s average yearly earnings per share was noted 39.49% at the time writing. With a float of $62.27 million, this company’s outstanding shares have now reached $70.77 million.
Let’s look at the performance matrix of the company that is accounted for 168 employees.
Zentalis Pharmaceuticals Inc (ZNTL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 12.31%, while institutional ownership is 113.65%. The most recent insider transaction that took place on May 31 ’24, was worth 114,972. In this transaction President, Interim CFO of this company sold 9,597 shares at a rate of $11.98, taking the stock ownership to the 633,680 shares. Before that another transaction happened on May 09 ’24, when Company’s Chief Medical Officer sold 3,356 for $12.62, making the entire transaction worth $42,353. This insider now owns 373,876 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Latest Financial update
If we go through the results of last quarter, which was made public on 3/31/2024, the company posted -1.85 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -1.04) by -0.81. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 39.49% per share during the next fiscal year.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 9.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.36, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.67 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) saw its 5-day average volume 0.9 million, a positive change from its year-to-date volume of 0.75 million. As of the previous 9 days, the stock’s Stochastic %D was 4.30%. Additionally, its Average True Range was 0.82.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 0.86%, which indicates a significant decrease from 1.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.92% in the past 14 days, which was lower than the 65.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.97, while its 200-day Moving Average is $14.66. Nevertheless, the first resistance level for the watch stands at $9.32 in the near term. At $9.80, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.08. If the price goes on to break the first support level at $8.56, it is likely to go to the next support level at $8.28. The third support level lies at $7.80 if the price breaches the second support level.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 71,026K shares outstanding in the company with a market cap of 627.73 million. Presently, the company’s annual sales total 0 K according to its annual income of -292,190 K. Last quarter, the company’s sales amounted to 40,560 K and its income totaled 10,070 K.
